GDET 1000% ROI Potential Breakout Alert On Cannabis News - $0.006 To $0.06 Analyst Target Price Opportunity


 

New York, NY -- April 26, 2019 -- InvestorsHub NewsWire -- www.nextbigticker.com -- GDET (USOTC: GDET) (GD Entertainment & Technology dba “GDET”) had a PPS $0.004 in March when the company announced its new cannabis subsidiary, “The Greenery.” The PPS shot up to over $0.02 on trading volume that put it in the top 20 most actively traded stocks on the OTC.  The company has been recommended at a Target PPS of $0.06 in a recent Analyst Report.  Management has executed on its CBD wellness and cosmetic product launch plan and announced today results from their 420 Product Launch Event in addition to announcing the availability of their CBD wellness and cosmetic products from their own online portal at www.thegreenery.com.  Since the $0.02 high, the PPS has pulled back on much lower volume and closed yesterday at $0.005.  Today, on evidence of management’s successful execution of their CBD wellness and cosmetic product launch plan, the PPS is turning north again on growing trading volume.  Now looks like a good time to BUY GDET for a potential 1000% ROI as the PPS goes up on continued business plan execution success toward the $0.06 Analyst Recommended Target PPS.




Bonus Stock News

Kali-Extracts, Inc. (USOTC: KALY) is also in the news today and another potential bounce play.  KALY is developing both cannabis pharmaceuticals and cannabis extracts for infusion into both inhouse consumer products and third party consumer products.  KALY has a patented cannabis extraction process that is the core of its business plan.  The company is already generating revenue from its partnership with Puration, Inc. (USOTC: PURA), the maker of EVERx CBD Sports Water.  Today the company announced expanding from their current CBD infused candy production to introducing a new Hemp Derived CBD Sun Tan Lotion.  The KALY PPS recently reached above $0.02 on top 20 most actively traded OTC volume when the company disclosed 4 years of pharmaceutical research and development.  The PPS has recently pulled back below $0.02 and seeing accumulation.   In December, the PPS reached almost $0.04.  The company continues to make extraordinary strides and it holds the potential to continue to see the PPS stair step up to a potential $0.10 before summer.  KALY under $0.02 is an attractive entry point for a double to possibly a 10x ROI.


DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Kali (CE) Charts.
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Kali (CE) Charts.